Staphylococcal Superantigens of the Enterotoxin Gene Cluster (egc) for Treatment of Stage IIIb Non-Small Cell Lung Cancer with Pleural Effusion

Clinics in Chest Medicine

Volumn 27, Issue 2, 2006, Pages 321-334

  Terman, David S ^a   Bohach, Gregory ^b   Vandenesch, Francois ^c   Etienne, Jerome ^c   Lina, Gerard ^c   Sahn, Steven A ^d  

^a Jenomic   (United States)

^b UNIVERSITY OF IDAHO   (United States)

^c INSERM   (France)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPYRETIC AGENT; CANCER ANTIBODY; CISPLATIN; DOPAMINE; DOXYCYCLINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METARAMINOL; NEUTRALIZING ANTIBODY; STAPHYLOCOCCUS ENTEROTOXIN; SUPERANTIGEN; TALC;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BINDING; DRUG INHIBITION; FEVER; GENE CLUSTER; GENE THERAPY; HUMAN; HYPOTENSION; HYPOXEMIA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MYALGIA; NAUSEA; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS; TACHYCARDIA; THORACOCENTESIS; UREMIA; VACCINATION;

ANIMALS; ANTIGENS, BACTERIAL; CARCINOMA, NON-SMALL-CELL LUNG; ENTEROTOXINS; HUMANS; LUNG NEOPLASMS; MULTIGENE FAMILY; PLEURAL EFFUSION; STAPHYLOCOCCUS; SUPERANTIGENS;

EID: 33646733615     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2006.01.001     Document Type: Review

References (96)

1. Chernow B., and Sahn S.A. Carcinomatous involvement of the pleura. Am J Med 63 (1977) 695-702
2. Sahn S.A., and Good J.T. Pleural fluid pH in malignant effusions. Ann Intern Med 108 (1988) 345-349
3. Walker-Renard P.B., Vaughan L.M., and Sahn S.A. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 120 (1994) 56-64
4. Sahn S.A. Malignancy metastatic to the pleura. Clin Chest Med 19 (1998) 351-361
5. Antony V., Loddenkemper R., Astoul P., et al. Management or malignant pleural effusions. Eur Respir J 18 (2001) 402-419
6. Light R.W. Pleural diseases. 4th edition (2001), Lippincott Williams & Wilkins, Philadelphia
7. Schrump D.S., and Nguyen D.M. Malignant pleural and pericardial effusions. In: DeVita V., Hellman S., and Rosenberg S.A. (Eds). Cancer, principles and practice of oncology (2001), Lippincott Williams & Wilkins, Philadelphia 2729-2744
8. Maghfoor I., Doll D.C., and Yarbro J.W. Effusions in clinical oncology. In: Abeloff M.D., Armitage J.O., Lichter M., and Niederhuber J.E. (Eds). Clinical oncology. 2nd edition (2000), Churchill Livingstone, New York 922-949
9. Putnam Jr. J.B., Walsh G.L., Swisher S.G., et al. Outpatient management of malignant pleural effusion by chronic indwelling pleural catheter. Ann Thorac Surg 69 (2000) 369-375
10. Putnam Jr. J.B., Light R.W., Rodriguez R.M., et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 86 (1999) 1992-1999
11. Heffner J.E., Nietert P.J., and Barbieri C. Pleural fluid pH as predictor of survival for patients with malignant pleural effusions. Chest 117 (2000) 79-86
12. Swanson K., Jett J.R., and Sahn S.A. Lung cancer with malignant pleural effusion: clinical and survival characteristics. Am J Respir Crit Care Med 165 (2002) A149
13. Burrows C.M., Mathews W.C., and Colt H.G. Predicting survival in patients with recurrent symptomatic malignant pleural effusion, an assessment of the prognostic values of physiologic, morphologic, and quality of life measures and extent of disease. Chest 117 (2000) 73-78
14. Belani C.P., Pajeau T.S., and Bennet C.L. Treating malignant pleural effusions cost consciously. Chest 113 (1998) 78S-85S
15. Ren S., Terman D.S., Bohach G., et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest 126 (2004) 1529-1539
16. Chu F.S., Thadhani K., Schantz E.J., and Bergdoll M.S. Purification and characterization of staphylococcal enterotoxin A. Biochemistry 5 (1966) 3281-3289
17. Marrack P., and Kappler J. The staphylococcal enterotoxins and their relatives. Science 248 (1990) 1066-1072
18. Bohach G.A., Fast D.J., Nelson R.D., and Schlievert P.M. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 17 (1990) 251-272
19. Proft T., and Fraser J.D. Bacterial superantigens. Clin Exp Immunol 133 (2003) 299-306
20. Papageorgiou A.C., and Acharya K.R. Superantigens as immunomodulators: recent structural insights. Structure 5 (1997) 991-996
21. Kotb M. Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity. Curr Opin Microbiol 1 (1998) 56-65
22. Petersson K., Forsberg G., and Walse B. Interplay between superantigens and immunoreceptors. Scand J Immunol 59 (2004) 345-355
23. Betley M.J., and Mekalanos J.J. Nucleotide sequence of the type A staphylococcal enterotoxin gene. J Bacteriol 170 (1988) 34-41
24. Fraser J.D., Urban R.G., Strominger J.L., and Robinson H. Zinc regulates the function of two superantigens. Proc Natl Acad Sci U S A 89 (1992) 5507-5511
25. Hopkins P.A., Fraser J.D., Pridmore A.C., et al. Superantigen recognition by HLA class II on monocytes up-regulates toll-like receptor 4 and enhances proinflammatory responses to endotoxin. Blood 105 (2005) 3655-3662
26. Gregory S., Zilber M., Charron D., and Gelin C. Human CD1a molecule expressed on monocytes plays an accessory role in the superantigen-induced activation of T lymphocytes. Hum Immunol 61 (2000) 193-201
27. Dohlsten M., Sundstedt A., Bjorklund M., et al. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer 54 (1993) 482-488
28. Munson S.H., Tremaine M.T., Betley M.J., et al. Identification and characterization of staphylococcal enterotoxin types G and I from Staphylococcus aureus. Infect Immun 66 (1998) 3337-3348
29. Jarraud S., Peyrat M.A., Lim A., et al. egc, a highly prevalent operon of enterotoxin gene, forms a putative nursery of superantigens in Staphylococcus aureus. J Immunol 166 (2001) 669-677
30. Becker K., Friedrich A.W., Lubritz G., et al. Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J Clin Microbiol 41 (2003) 1434-1439
31. Ferry T., Thomas D., Genestier A.L., et al. Comparative prevalence of superantigen genes in Staphylococcus aureus isolates causing sepsis with and without septic shock. Clin Infect Dis 41 (2005) 771-777
32. Holtfreter S., Bauer K., Thomas D., et al. egc-Encoded superantigens from Staphylococcus aureus are neutralized by human sera much less efficiently than are classical staphylococcal enterotoxins or toxic shock syndrome toxin. Infect Immun 72 (2004) 4061-4071
33. Terman D.S., Yamamoto T., Mattioli M., et al. Extensive necrosis of spontaneous canine mammary adenocarcinoma after extracorporeal perfusion over Staphylococcus aureus Cowans I. I. Description of acute tumoricidal response: morphologic, histologic, immunohistochemical, immunologic, and serologic findings. J Immunol 124 (1980) 795-805
34. Terman D.S., Yamamoto T., Tillquist R.L., et al. Tumoricidal response induced by cytosine arabinoside after plasma perfusion over protein A. Science 209 (1980) 1257-1259
35. Terman D.S. Protein A and staphylococcal products in neoplastic disease. Crit Rev Oncol Hematol 4 (1985) 103-124
36. Terman D.S., and Bertram J.H. Antitumor effects of immobilized protein A and staphylococcal products: linkage between toxicity and efficacy, and identification of potential tumoricidal reagents. Eur J Cancer Clin Oncol 21 (1985) 1115-1122
37. Terman D.S. Preparation of protein A immobilized on collodion-coated charcoal and plasma perfusion system for treatment of cancer. Methods Enzymol 137 (1988) 496-515
38. Terman D.S., and Stone J.S. Staphylococcal and streptococcal exotoxin (superantigen) induced regression of established tumor in vivo. Proceedings of International Workshop on Superantigens (1993), Cancer Research Institute, New York 12-14
39. Kalland T., Dohlsten M., Lind P., et al. Monoclonal antibodies and superantigen: a novel therapeutic approach. Med Oncol Tumor Pharmacother 10 (1993) 37-47
40. Penna C., Dean P.A., and Nelson H. Antitumor X anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. Cancer Res 54 (1994) 2738-2743
41. Newell K.A., Ellenhorn J.D., Bruce D.S., and Bluestone J.A. In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor. Proc Natl Acad Sci U S A 88 (1991) 1074-1078
42. Dohlsten M., Lando P.A., Bjork P., et al. Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother 41 (1995) 162-168
43. Kominsky S.L., Torres B.A., Hobeika A.C., et al. Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer. Int J Cancer 94 (2001) 834-841
44. Perabo F.G., Willert P.L., Wirger A., et al. Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma. Anticancer Res 25 (2005) 3565-3573
45. Pulaski B.A., Terman D.S., Khan S., et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 60 (2000) 2710-2715
46. Huang C., Yu H., Wang Q., et al. Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene. Cancer Sci 95 (2004) 160-167
47. Wang Q., Yu H., Zhang L., et al. Potent antitumor effects have been seen with linked tumor cells transduced with heat shock protein 70, IL-18: vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response. J Cancer Res Clin Oncol 127 (2001) 718-726
48. Ma W., Yu H., Wang Q., et al. A novel approach for cancer immunotherapy: tumor cells with anchored superantigens SEA generate effective antitumor immunity. J Clin Immunol 24 (2004) 294-301
49. Wahlsten J.L., Mills C.D., and Ramakrishnan S. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. J Immunol 161 (1998) 6761-6767
50. Yi P., Yu H., Ma W., et al. Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin: a dual-anchored tumor cell vaccine and its antitumor effect. Cancer 103 (2005) 1519-1528
51. Ma W., Yu H., Wang Q., et al. In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein. Cancer Immunol Immunother 53 (2004) 118-124
52. Whang Z., Claden N., Terman D.S., et al. Enhancement of DNA vaccine potency by administration of an antigen linked to SEB gene in mouse and rabbit models. International Symposium on Papilloma Viral Infection. Paris, France, October 4, 2002
53. Dow S.W., Elmslie R.E., Willson A.P., et al. In vivo tumor transfection with superantigens plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 101 (1998) 2406-2413
54. Thamm D.H., Kurzman I.D., Macewen E.G., et al. Intralesional lipid-complexed cytokine/superantigens immunogene therapy for spontaneous canine tumors. Cancer Immunol Immunother 52 (2003) 473-480
55. Shu S., Krinock R.A., Fox B.A., et al. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 152 (1994) 1277-1288
56. Plautz G.E., Barnett G.H., Miller D.W., et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 89 (1998) 42-51
57. Hansson J., Ohlsson L., Persson R., et al. Genetically engineered superantigens as tolerable antitumor agents. Proc Natl Acad Sci U S A 94 (1997) 2489-2494
58. Dohlsten M., Hedlund G., Akerblom E., et al. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A 88 (1991) 9287-9291
59. Dohlsten M., Abrahmsen L., Bjork P., et al. Monoclonal antibody-superantigens fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci U S A 91 (1994) 8945-8949
60. Takemura S., Kudo T., Asano R., et al. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol Immunother 51 (2002) 33-44
61. Terman D.S., Young J.B., Shearer W.T., et al. Preliminary observations of the effects on breast adenocarcinoma of plasma perfused over immobilized protein A. N Engl J Med 305 (1981) 1195-1200
62. Young J.B., Ayus J.C., Miller L.K., et al. Cardiopulmonary toxicity in patients with breast carcinoma during plasma perfusion over immobilized protein A: pathophysiology of reaction and attenuating methods. Am J Med 75 (1983) 278-288
63. Finegold M.J. Interstitial pulmonary edema: an electron microscopic study of the pathology of staphylococcal enterotoxemia in Rhesus monkeys. Lab Invest 16 (1967) 912-924
64. Giantonio B.J., Alpaugh R.K., Schultz J., et al. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol 15 (1997) 1994-2007
65. Persson B., Persson R., Weiner L.M., et al. Overview of clinical trials employing antibody-targeted superantigens. Adv Drug Deliv Rev 31 (1998) 143-152
66. Newton D.W., Dohlsten M., Olsson C., et al. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity. J Immunol 157 (1996) 3988-3994
67. Newton D.W., Dohlsten M., Lando P.A., et al. MHC class II-independent, Vbeta-specific activation of T cells by SAgsmutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma. Int J Mol Med 1 (1998) 157-162
68. Alpaugh R.K., Schultz J., McAleer C., et al. Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies. Clin Cancer Res 4 (1998) 1903-1914
69. Cheng J.D., Babb J.S., Langer C., et al. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J Clin Oncol 22 (2004) 602-609
70. Erlandsson E., Andersson K., Cavallin A., et al. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy. J Mol Biol 333 (2003) 893-905
71. Socinski M.A., Morris D.E., Masters G.A., et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123 (2003) 226S-243S
72. Bunn P.A. Chemotherapy for advanced non-small cell lung cancer: who, what, when, why?. J Clin Oncol 20 (2002) 23S-33S
73. Sahn S.A. Talc should be used for pleurodesis. Am J Respir Crit Care Med 162 (2000) 2023-2024
74. DeGrendele H.C., Estess P., and Siegelman M.H. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 278 (1997) 672-674
75. DeGrendele H.C., Kosfiszer M., Estess P., et al. CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. J Immunol 159 (1997) 2549-2553
76. Siegleman M.H., Stanescu D., and Estess P. The CD44-initiated pathway of T cell extravasation uses VLA4 but not LFA-1 for firm adhesion. J Clin Invest 105 (2000) 683-690
77. Miethke T., Wahl C., Holzmann B., et al. Bacterial superantigens induce rapid and T cell receptor V beta-selective down-regulation of L-selectin (gp90Mel-14) in vivo. J Immunol 151 (1993) 6777-6782
78. Kagamu H., and Shu S. Purification of L-selectin (low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 160 (1998) 3444-3452
79. Von Andrian U.H., and Mackay C.R. T cell function and migration. N Engl J Med 343 (2000) 1020-1033
80. Tikhonov I., Moiz K., Wallance M., et al. Staphylococcal superantigens induce lymphotactin production by human CD4 + and CD8 + T-cells. Cytokine 16 (2001) 73-78
81. Fujisawa N., Hayashi S., Kurdowska A., et al. Staphylococcal enterotoxin A-induced injury of human lung endothelial cells and IL-8 accumulation are mediated by TNFα. J Immunol 161 (1998) 5627-5632
82. Miura T., Shimada T., Tanaka K., et al. Lymphatic drainage of carbon particles injected into the pleural cavity of the monkey as studied by video-assisted thoracoscopy and electron microscopy. J Thorac Cardiovasc Surg 120 (2000) 437-447
83. Dohlsten M., Hedlund G., Segren S., et al. Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor. Eur J Immunol 21 (1991) 1229-1233
84. Haffner A.C., Zepter K., and Elmets C.A. Major histocompatibility complex class I molecule serves as a ligand for presentation of the superantigen staphylococcal enterotoxin B to T cells. Proc Natl Acad Sci U S A 93 (1996) 3037-3042
85. Lanne B., Jondal M., and Karlsson K.A. Gal alpha 4Gal-binding antibodies: specificity and use for the mapping of glycolipids of Burkitt lymphoma and other human tumors. Glycobiology 6 (1996) 423-431
86. Chatterjee S., Khullar M., and Shi W.Y. Digalactosylceramide is the receptor for staphylococcal enterotoxin-B in human kidney proximal tubular cells. Glycobiology 5 (1995) 327-333
87. Lamphear J.G., Stevens K.R., and Rich R.R. Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule. J Immunol 160 (1998) 615-623
88. Passlick B., Pantel K., Kubuschok B., et al. Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. Eur J Cancer 32A (1996) 141-145
89. Vogetseder W., Feichtinger H., Schulz T.F., et al. Expression of 7F7-antigen, a human adhesion molecule identical to intercellular adhesion molecule-1 (ICAM-1) in human carcinomas and their stromal fibroblasts. Int J Cancer 43 (1989) 768-773
90. Tomita Y., Nishiyama T., Watanabe H., et al. Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: possible significance in host immune responses. Int J Cancer 46 (1990) 1001-1006
91. Guo Y.J., Che X.Y., Shen F., et al. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med 3 (1997) 451-455
92. Mortarini R., Belli F., Parmiani G., et al. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells: comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations. Int J Cancer 45 (1990) 334-341
93. Kuppner M.C., van Meir E., Hamou M.F., et al. Cytokine regulation of intercellular adhesion molecule-1 (ICAM-1) expression on human glioblastoma cells. Clin Exp Immunol 81 (1990) 142-148
94. Jedrzkiewicz S., Kataeva G., Hogaboam C.M., et al. Superantigen immune stimulation evokes epithelial monocyte chemoattractant protein 1 and RANTES production. Infect Immun 67 (1999) 6198-6202
95. Nagelkerken L., Gollob K.J., Tielemans M., et al. Role of transforming growth factor-beta in the preferential induction of T helper cells of type 1 by staphylococcal enterotoxin B. Eur J Immunol 23 (1993) 2306-2310
96. Lee Y.C., Lane K.B., Parker R.E., et al. Transforming growth factor beta(2) (TGF beta(2)) produces effective pleurodesis in sheep with no systemic complications. Thorax 55 (2000) 1058-1062